The US FDA anticipates that sponsors will generally not need to obtain pre-market approval for the output of prescription drug-use-related software, although the agency is also encouraging they use the voluntary advisory comment process in certain cases.
In officially announcing its discussion proposal in a Federal Registernotice scheduled to be published Nov. 20, FDA recommended drugmakers use the advisory process when "the use of the prescription...